Cellectis to open labs and offices in Manhattan

Published: 9-Apr-2015
Research & Development

Will support the development of smart drugs for cancer


Cellectis, a France headquartered gene-editing company, has established a subsidiary, Cellectis, Inc, in New York at the Alexandria Center for Life Science, located on Manhattan’s east side.

The 12,000ft2 (approximately 1,100m2) US headquarters includes research laboratories to support the development of the company's Chimeric Antigen Receptor T-cell (CAR-T) pipeline for the treatment of cancer, as well as other types of therapeutic indications. It will be officially opened on 16 April.

Dr André Choulika, Founder, Chief Executive and Chairman of Cellectis, said New York City is one of the fastest-expanding biotech hubs in the world and the Alexandria Center for Life Science is surrounded by renowned academic and medical institutions, leading commercial companies in the life sciences industry as well as a robust financial market.

Cellectis uses gene editing to produce CAR-T cells with unique qualities and features, including allogeneic or 'off-the-shelf' versions, which can be produced more efficiently and shipped to patients worldwide.

  • Companies:
  • Cellectis
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Read more
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach

Trending Articles

  1. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  2. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  3. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  4. Cresset creates new Vice President role to lead its AI strategy Dr Mutlu Dogruel joins from Microsoft, where he was responsible for empowering organisations to implement scalable AI solutions into their workflow
  5. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Research & Development

Pfizer and Cellectis enter cancer immunotherapy collaboration

Partners will use Cellectis’ allogeneic CAR-T technology to develop cancer drugs
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

A hothouse for drug r&d

Growing vaccines in fertilised chicken eggs is expensive and time-consuming and involves educated guesswork regarding the strain of virus to be vaccinated against. In contrast, plants can be used to produce large quantities of vaccines on a much shorter timescale, and because the virus-like particles (VLPs) produced lack the core genetic material of the virus, they are non-infectious and unable to reproduce
Research & Development

Cellectis and Lonza reach significant bioresearch milestone

Removal of endogenous glutamine synthetase (GS) in Lonza’s proprietary host cell line will facilitate the creation of highly productive recombinant cell lines
Research & Development

Cellectis and VitamFero sign five-year licensing agreement

To develop vaccines against parasitic infection
Research & Development

Cellectis bioresearch sets up US subsidiary

Expands presence in North American life sciences market
Research & Development

Lonza and Cellectis Bioresearch sign r&d agreement

Cellectis to use meganucleases to deactivate the glutamine synthetase (GS) in Lonza\'s CHOK1SV
Subscribe now